Skip to main content
← All resources

Case study · With iBET and Eppendorf

Hybrid modeling for scalable cardiomyocytes expansion

A cell therapy use case performed with iBET and Eppendorf, comparing a hybrid model against a statistical linear model on hiPSC-derived cardiomyocyte expansion.

  • Cell therapy
  • Optimization
DO EFFECT ON FINAL VCDLINEAR MODELMISSEDHYBRID MODELCAPTUREDBIOREACTOR RUNS6 RUNS · 3 DO CONDITIONSENOUGH TO MODEL
  • 6

    Bioreactor runs were enough to predict full VCD, glucose, lactate and LDH profiles

  • 3

    Dissolved oxygen conditions distinguished, capturing the non-linear DO effect a linear model missed

  • Optimal feed and DO combination found in silico, maximizing growth while minimizing media

The challenge

Every experiment counts

Cell therapies are resource-intensive, with high material costs and outcomes highly sensitive to oxygen levels and feed rates. Scientists must explore the design space with limited experimental capacity.

The approach

Hybrid versus linear, then simulate

A hybrid model was trained on runs in Eppendorf DASGIP® parallel bioreactors across three DO conditions, compared with a linear model for final-day VCD, and used to simulate feed and DO scenarios.

  • 6 bioreactor runs
  • 3 DO conditions
  • VCD final-day target

Get the full results

Download the full case study, with project outline, analysis, and case results.